White Paper

Platinum Market Dynamics and Their Impact on Cancer Treatment Costs

Platinum-based chemotherapy drugs remain an essential pillar of modern cancer treatment. Active pharmaceutical ingredients (APIs) such as cisplatin, carboplatin, and oxaliplatin are used worldwide and play a critical role in treating a broad range of cancers. Because these APIs contain a significant proportion of platinum, their cost structure is highly sensitive to movements in platinum prices.

For many years, platinum prices remained relatively stable, allowing pharmaceutical manufacturers, buying groups, and healthcare systems to operate within predictable economic frameworks. However, the unprecedented platinum rally in 2025 fundamentally changed this situation. Driven by metal liquidity tightness, surging demand, and speculative activity, platinum prices increased dramatically, placing significant pressure on the economics of platinum-based pharmaceuticals.

The resulting impact has been felt throughout the healthcare value chain. API costs rose sharply, tender-based procurement systems struggled to adapt, and supply shortages emerged in several markets.

This paper examines the characteristics of platinum as a commodity, the drivers behind the 2025 platinum rally, the consequences for pharmaceutical pricing and supply, and the measures that can help stabilize access to these critical cancer therapies.